Patents Assigned to ISIS Pharmaceuticals Inc.
  • Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
    Patent number: 9096851
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: August 4, 2015
    Assignees: Excaliard Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Frier
  • Chimeric oligomeric compounds and their use in gene modulation
    Patent number: 9096636
    Abstract: Oligomer compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capble of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes at least one nucleotide comprising a chimeric organic composition. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleotide comprising a chimeric organic composition.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: August 4, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Stanley T. Crooke
  • MODULATION OF UBE3A-ATS EXPRESSION
    Publication number: 20150191723
    Abstract: Certain embodiments are directed to methods and compounds for inhibiting UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A). Such methods and compounds are useful for inducing expression of paternal UBE3A in cells and animals.
    Type: Application
    Filed: June 25, 2013
    Publication date: July 9, 2015
    Applicants: Baylor College of Medicine, Isis Pharmaceuticals, Inc.
    Inventors: Frank Rigo, Amanda Ward, Linyan Meng, Arthur L. Beaudet
  • BICYCLIC CYCLOHEXOSE NUCLEIC ACID ANALOGS
    Publication number: 20150191727
    Abstract: The present invention provides bicyclic cyclohexose nucleoside analogs and oligomeric compounds comprising these nucleoside analogs. These bicyclic nucleoside analogs are useful for enhancing properties of oligomeric compounds including nuclease resistance.
    Type: Application
    Filed: March 18, 2015
    Publication date: July 9, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Michael T. Migawa, Punit P. Seth, Eric E. Swayze, Bruce S. Ross, Quanlai Song, Mingming Han
  • MODULATION OF APOLIPOPROTEIN (a) EXPRESSION
    Publication number: 20150184156
    Abstract: Compounds, compositions and methods are provided for modulating the expression of apolipoprotein(a). The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein(a). Methods of using these compounds for modulation of apolipoprotein(a) expression and for diagnosis and treatment of disease associated with expression of apolipoprotein(a) are provided.
    Type: Application
    Filed: March 12, 2015
    Publication date: July 2, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Rosanne M. Crooke, Mark J. Graham
  • ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 4 EXPRESSION
    Publication number: 20150184164
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of fibroblast growth factor receptor 4 (FGFR4) mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a metabolic disease, or a symptom thereof.
    Type: Application
    Filed: December 4, 2014
    Publication date: July 2, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Sanjay Bhanot, Xing-Xian Yu, Michael L. McCaleb
  • MODULATION OF TRANSTHYRETIN EXPRESSION
    Publication number: 20150184157
    Abstract: Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.
    Type: Application
    Filed: February 5, 2015
    Publication date: July 2, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Vickie L. Brown-Driver, Ravi Jain
  • OLIGOMERIC COMPOUNDS COMPRISING BICYCLIC NUCLEOTIDES AND USES THEREOF
    Publication number: 20150184153
    Abstract: The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.
    Type: Application
    Filed: April 22, 2013
    Publication date: July 2, 2015
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Eric E. Swayze
  • COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION
    Publication number: 20150176007
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Application
    Filed: February 27, 2015
    Publication date: June 25, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • MODULATION OF ENHANCER RNA MEDIATED GENE EXPRESSION
    Publication number: 20150176005
    Abstract: Disclosed herein are methods and compounds for inhibiting gene expression by inhibiting enhancer RNAs (eRNAs). Such methods and compounds are useful for reducing expression of certain genes, many of which are associated with a variety of diseases and disorders.
    Type: Application
    Filed: May 22, 2013
    Publication date: June 25, 2015
    Applicants: The Regents of the University of California, Isis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Christopher K. Glass, Michael G. Rosenfeld, Wenbo Li, Michael T. Lam
  • Modulation of transthyretin expression
    Patent number: 9061044
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: June 23, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Susan M. Freier
  • ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION
    Publication number: 20150167008
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.
    Type: Application
    Filed: February 24, 2015
    Publication date: June 18, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: C. Frank Bennett, Kenneth W. Dobie
  • OLIGOMERIC COMPOUNDS AND METHODS
    Publication number: 20150167006
    Abstract: The present invention provides oligomeric compounds and uses thereof. In certain embodiments, such oligomeric compounds are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds or as RNAi compounds.
    Type: Application
    Filed: February 10, 2015
    Publication date: June 18, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Eric E. Swayze, Balrkishen Bhat, Walter F. Lima, Thazha P. Prakash, Garth A. Kinberger
  • METHODS FOR TREATING HYPERCHOLESTEROLEMIA
    Publication number: 20150167005
    Abstract: Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and/or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.
    Type: Application
    Filed: November 12, 2014
    Publication date: June 18, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Susan M. Freier, Rosanne M. Crooke, Mark J. Graham, Kristina M. Lemonidis, Sanjay Bhanot, Diane Tribble, Andrew T. Watt
  • Compositions and their uses directed to huntingtin
    Patent number: 9057066
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's disease progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntingtin's disease in an individual susceptible to Huntingtin's Disease. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: June 16, 2015
    Assignees: Isis Pharmaceuticals, Inc., CHDI Foundation Inc.
    Inventors: Gene Hung, Janet M. Leeds, C. Frank Bennett, Susan M. Freier
  • MODULATION OF HUNTINGTIN EXPRESSION
    Publication number: 20150159155
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Application
    Filed: October 30, 2014
    Publication date: June 11, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • MODIFIED NUCLEOSIDES, ANALOGS THEREOF AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM
    Publication number: 20150159163
    Abstract: The present invention provides modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom. More particularly, the present invention provides modified nucleosides and analogs thereof that are useful for incorporation at the terminus of an oligomeric compound. Such oligomeric compounds can also be included in a double stranded composition. In some embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Application
    Filed: February 20, 2015
    Publication date: June 11, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION
    Publication number: 20150152411
    Abstract: Disclosed herein are antisense compounds and methods for decreasing apo(a) to treat, prevent, ameliorate diseases, disorders or conditions related to apo(a) or Lp(a). Certain diseases, disorders or conditions related to apo(a) or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The antisense compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
    Type: Application
    Filed: May 23, 2013
    Publication date: June 4, 2015
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Rosanne M. Crooke, Mark J. Graham, Susan M. Freier
  • Short antisense compounds with gapmer configuration
    Patent number: 9045754
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: June 2, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • ANTISENSE MODULATION OF GCCR EXPRESSION
    Publication number: 20150141493
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of GCCR mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.
    Type: Application
    Filed: October 24, 2014
    Publication date: May 21, 2015
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Susan M. Freier, Sanjay Bhanot